FoundationOne Heme
DNA/RNA comprehensive genomic profiling LDT for hematologic neoplasms and other source-defined indications.
- Developer
- Foundation Medicine
- Intended use
- Other
- Cancer scope
- Not reported
- Specimen
- Bone marrow aspirate, FFPE tumor tissue, Peripheral whole blood
- Molecular modality
- DNA mutation, RNA
- Current version
- FoundationOne Heme current 406-DNA/265-RNA LDT (2026)
- Evidence context
- 1 structured studies · 0 indexed performance results · 2 sources
Why can reported performance numbers differ? MDI keeps each result attached to its study, population, stage or stratum, test version and source rather than treating performance as a fixed property of the test.